Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation

Hematology

Volumn 12, Issue 2, 2007, Pages 117-121

  Zhu, Kang Er ^a   Li, Jun Ping ^a   Zhang, Tao ^a   Zhong, Juan ^a   Chen, Jie ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Allogeneic; Hematopoietic stem cell transplantation; Major ABO incompatibility; Pure red cell aplasia

Indexed keywords

CD20 ANTIBODY; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP B; BLOOD GROUP O; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DONOR SELECTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; ERYTHROCYTE APLASIA; FEMALE; HERPES VIRUS INFECTION; HUMAN; INCIDENCE; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PLASMAPHERESIS; PREOPERATIVE CARE; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BETA-THALASSEMIA; BLOOD GROUP INCOMPATIBILITY; BUSULFAN; CHILD, PRESCHOOL; CYCLOSPORINE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; PLASMA EXCHANGE; RED-CELL APLASIA, PURE; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 34247182607     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330601111540     Document Type: Article

References (8)

1. Gmür, J., Burger, J. and Schaffmer, A. (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood, 75, pp. 290-295.
2. Lee, JH, Lee, KH and Kim, S. (2000) Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant, 25, pp. 179-184.
3. Huang, XJ, Chen, ZX and Wang, W. (2002) Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Chinese J Hematol, 26, pp. 548-550.
4. Wernet, D. and Mayer, G. (1992) Isoagglutins following ABO-incompatible bone marrow transplantation. Vox Sang, 62, pp. 176-179.
5. Sieff, C., Bicknell, D. and Caine, G. (1982) Changes in surface antigen express during hemopoietic differentiation. Blood, 60, pp. 703-713.
6. Benjamin, RJ, Connors, JM and McGurk, S. (1998) Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant, 4, pp. 151-156.
7. Maschan, AA, Skorobogatova, EV and Balashow, DN (2002) Successful treatment of pure red cell aplasia with a single dose of Rituximab in a child after major ABO-incompatible peripheral stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant, 30, pp. 405-407.
8. Zhu, KE, Chen, J. and Chen, ST (2005) Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: A case report and literature review. Hematology, 10, pp. 365-370.